Prostate specific antigen: biology, biochemistry and available commercial assays - PubMed (original) (raw)

Review

. 2001 Nov;38(Pt 6):633-51.

doi: 10.1258/0004563011901055.

Affiliations

• PMID: 11732646
• DOI: 10.1258/0004563011901055

Review

Prostate specific antigen: biology, biochemistry and available commercial assays

A M Ward et al. Ann Clin Biochem. 2001 Nov.

Abstract

Prostate specific antigen (PSA) is the marker of choice in the management of prostate cancer. However, PSA is not a simple molecule, existing in the serum in five isoforms and a number of molecular configurations and complexes. The elucidation of the biochemistry of PSA has increased the potential use of the marker in the diagnosis of prostate malignancy. This review summarizes the clinical use of PSA in the management of prostate disease and the assays available in the UK. Assay calibration in relation to the World Health Organization 1st International Standard for Prostate Specific Antigen (90:10) has increased conformity between the various commercial assay kits, and the non-equimolar kits have largely been superseded or withdrawn. Special reference is made to evaluations performed on behalf of the Medical Devices Agency of the Department of Health.

PubMed Disclaimer

Similar articles

• [Value of free/total prostate specific antigen in the early diagnosis of prostate cancer (study of 105 patients)].
  de la Taille A, Houlgatte A, Houdelette P, Berlizot P, Ramirez J, Ricordel I. de la Taille A, et al. Prog Urol. 1997 Apr;7(2):240-5. Prog Urol. 1997. PMID: 9264766 French.
• [Prostate-specific antigen as a tumor marker of prostate carcinoma].
  Wymenga LF, Mensink HJ. Wymenga LF, et al. Ned Tijdschr Geneeskd. 1999 Aug 21;143(34):1733-8. Ned Tijdschr Geneeskd. 1999. PMID: 10494319 Review. Dutch.
• Issues on standardization of immunoassays for prostate-specific antigen: a review.
  Graves HC. Graves HC. Clin Invest Med. 1993 Dec;16(6):415-24. Clin Invest Med. 1993. PMID: 7516830 Review.

Cited by

• Evaluation of molecular species of prostate-specific antigen complexed with immunoglobulin M in prostate cancer and benign prostatic hyperplasia.
  Goč S, Janković M. Goč S, et al. Dis Markers. 2013;35(6):847-55. doi: 10.1155/2013/923819. Epub 2013 Dec 3. Dis Markers. 2013. PMID: 24367138 Free PMC article.
• Hybrids of a genetically engineered antibody and a carbon nanotube transistor for detection of prostate cancer biomarkers.
  Lerner MB, D'Souza J, Pazina T, Dailey J, Goldsmith BR, Robinson MK, Johnson AT. Lerner MB, et al. ACS Nano. 2012 Jun 26;6(6):5143-9. doi: 10.1021/nn300819s. Epub 2012 May 17. ACS Nano. 2012. PMID: 22575126 Free PMC article.
• Consistency and diagnostic accuracy of 4 assays in the detection of the total and free prostate-specific antigen.
  Deng L, Yue D, Wang X, Li H. Deng L, et al. Transl Androl Urol. 2023 Feb 28;12(2):261-270. doi: 10.21037/tau-23-29. Epub 2023 Feb 23. Transl Androl Urol. 2023. PMID: 36915871 Free PMC article.
• Translation of proteomic biomarkers into FDA approved cancer diagnostics: issues and challenges.
  Füzéry AK, Levin J, Chan MM, Chan DW. Füzéry AK, et al. Clin Proteomics. 2013 Oct 2;10(1):13. doi: 10.1186/1559-0275-10-13. Clin Proteomics. 2013. PMID: 24088261 Free PMC article.
• Galectin-3: a possible complementary marker to the PSA blood test.
  Balan V, Wang Y, Nangia-Makker P, Kho D, Bajaj M, Smith D, Heilbrun L, Raz A, Heath E. Balan V, et al. Oncotarget. 2013 Apr;4(4):542-9. doi: 10.18632/oncotarget.923. Oncotarget. 2013. PMID: 23625538 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Atypon

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information

• Research Materials

  • NCI CPTC Antibody Characterization Program

• Miscellaneous

  • NCI CPTAC Assay Portal